ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study
Start date:March 2020 Co-ordinated by:
University of Oxford Main trial site:
Royal Infirmary of Edinburgh, Western General Hospital, St John's Hospital
Infectious disease is the single biggest cause of death worldwide. New infectious agents, such as the SARS, MERS and other novel coronavirus’ require investigation to understand pathogen biology and pathogenesis in the host. Even for known infections, resistance to antimicrobial therapies is widespread, and treatments to control potentially deleterious host responses are lacking.
The ISARIC study aims to develop a mechanistic understanding of disease processes, so that risk factors for severe illness can be identified and treatments can be developed.
When patients are confirmed to have corona virus, the research team will ask them to participate into this study. The participant will be consenting to provide blood, urine and faecal samples throughout their admission at day 1, 3 and 9, with a final follow up completed at day 28.
Local PI
Professor Alasdair Gray
Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department
Research Team
Rachel O'Brien
Lead Research Nurse
Nicky Freeman
Senior Research Nurse
Caroline Blackstock
AMU Senior Research Nurse
Emily Godden
Senior Research Nurse - Renal/Acute Medicine
Nicholas Fethers
Research Administrator
Michelle Coakley
Senior Research Nurse - Stroke/Neurosurgery
Julia Grahamslaw
Lead Research Nurse
More EMERGE Trials
To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.
PRECISE-CTCA Trial
To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.
DASH Trial
DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.
Assisting in identifying patients with Humeral shaft fractures in the ED by screening.
Giving patient information sheets to introduce the study, so patient has had adequate time to read and make decision about going into the trial before going to the fracture clinic.